Skip to main content

Table 3 Cancer Characteristics; treatment response assessment

From: Camrelizumab for cancers in patients living with HIV: one-single center experience

Patient

Tumor type

PD-1 cycle

Response

Survival (yes/no)

TMB (mutes/Mb)

MSI

PD-L1 status (CPS)

Combined chemotherapy (yes/no)

#1

Seminoma

4

Progression

Yes

N/A

N/A

N/A

No

#2

Gastric cardia cancer

5

Stable

Yes

N/A

N/A

N/A

No

#3

Renal carcinoma

8

Progression

Yes

2.74

MSS

< 1

No

#4

Rectal carcinoma

7

Progression

No

N/A

N/A

N/A

No

#5

Non-Hodgkin lymphoma

8

PR

Yes

8.21

MSS

20

Yes

#6

Anal cancer

6

Progression

Yes

N/A

N/A

N/A

No

#7

Non-Hodgkin lymphoma

7

PR

Yes

N/A

N/A

N/A

Yes

#8

Cervical cancer

6

Stable

Yes

N/A

N/A

N/A

No

#9

Hepatocellular carcinoma

7

PR

Yes

N/A

N/A

N/A

No

#10

Renal carcinoma

8

Progression

No

N/A

N/A

N/A

No

#11

Renal pelvic cancer

6

Progression

No

22.80

MSS

< 1

No

#12

Gastric cancer

12

Stable

Yes

N/A

N/A

N/A

Yes

#13

Renal carcinoma

14

Stable

Yes

N/A

N/A

N/A

No

#14

Penile carcinoma

11

Stable

Yes

N/A

N/A

N/A

No

#15

Bladder cancer

12

Stable

Yes

7.30

MSS

< 1

No

#16

Bladder cancer

26

CR

Yes

4.56

MSS

10

Yes

#17

Bile duct cancer

10

PR

Yes

N/A

N/A

N/A

No

#18

Bladder cancer

7

Progression

Yes

N/A

N/A

N/A

No

#19

Bladder cancer

5

Progression

No

N/A

N/A

N/A

No

#20

Ureteral cancer

8

Progression

Yes

20.98

MSS

2

No

#21

Hepatocellular carcinoma

7

PR

Yes

17.33

MSS

80

No

#22

Bladder cancer

6

Stable

Yes

N/A

N/A

N/A

Yes

#23

Bladder cancer

11

CR

Yes

N/A

N/A

N/A

Yes

#24

Renal cancer

6

PR

Yes

N/A

N/A

N/A

No